person · Reporting owner

Dier Mardi

Disclosed activity across 7 companies

Tapewire entity: 62346
SEC CIK: 0001574591

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACELYRIN, Inc.SLRN · Entity 79310	CFO and CBO	May 09, 2023	May 11, 2023
Adamas Pharmaceuticals IncADMS · Entity 133085	Director	June 02, 2021	June 04, 2021
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	EVP and CFO	March 04, 2026	March 07, 2026
Oric Pharmaceuticals, Inc.ORIC · Entity 4765	Director	January 02, 2026	January 06, 2026
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 12, 2025	June 13, 2025
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	CFO & Executive Vice President	October 14, 2022	October 17, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACELYRIN, Inc.

Report date May 09, 2023 · Filed May 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,556	Reported balance After 2023-05-09 transaction · row 1 1 source row Row 1 · 2023-05-09 · Purchase · Acquired 5,556 · Balance 5,556 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F2: The shares are held of record by one of the Reporting Person's children.
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F3: The shares are held of record by another one of the Reporting Person's children.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	0	Reported balance After 2023-05-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-05-09 · Other · Disposed 673,621 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	673,621	Reported balance After 2023-05-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-05-09 · Other · Acquired 673,621 · Balance 673,621 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	0	Reported balance After 2023-05-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-05-09 · Other · Disposed 85,226 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	85,226	Reported balance After 2023-05-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-05-09 · Other · Acquired 85,226 · Balance 85,226 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").

F2: The shares are held of record by one of the Reporting Person's children.

F3: The shares are held of record by another one of the Reporting Person's children.

F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Adamas Pharmaceuticals Inc

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Grant · Acquired 5,000 · Balance 10,000 F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01	Direct	10,000	Reported balance After 2021-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

MADRIGAL PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,490	Ending reported balance After 2026-03-06 transaction · row 13 13 source rows · reconciled sequence Row 1 · 2026-03-04 · Grant · Acquired 5,215 · Balance 14,472 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Row 2 · 2026-03-06 · Sale · Disposed 646 · Balance 13,826 F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Row 3 · 2026-03-06 · Sale · Disposed 40 · Balance 13,786 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 4 · 2026-03-06 · Sale · Disposed 420 · Balance 13,366 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 5 · 2026-03-06 · Sale · Disposed 80 · Balance 13,286 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive. Row 6 · 2026-03-06 · Sale · Disposed 160 · Balance 13,126 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive. Row 7 · 2026-03-06 · Sale · Disposed 40 · Balance 13,086 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 8 · 2026-03-06 · Sale · Disposed 120 · Balance 12,966 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive. Row 9 · 2026-03-06 · Sale · Disposed 116 · Balance 12,850 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive. Row 10 · 2026-03-06 · Sale · Disposed 160 · Balance 12,690 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive. Row 11 · 2026-03-06 · Sale · Disposed 80 · Balance 12,610 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive. Row 12 · 2026-03-06 · Sale · Disposed 80 · Balance 12,530 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive. Row 13 · 2026-03-06 · Sale · Disposed 40 · Balance 12,490 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.80 · Expires 2036-03-04	Direct	6,519	Reported balance After 2026-03-04 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-03-04 · Grant · Acquired 6,519 · Balance 6,519 F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.

F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Oric Pharmaceuticals, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01	Direct	40,000	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Prelude Therapeutics Inc

Report date June 12, 2025 · Filed June 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-06-11	Direct	38,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Ultragenyx Pharmaceutical Inc.

Report date October 14, 2022 · Filed October 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	66,695	Reported balance After 2022-10-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-10-14 · Sale · Disposed 1,629 · Balance 66,695 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 39,563 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	10	Reported balance After 2020-06-18 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-06-18 · Grant · Acquired 10 · Balance 10 F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 10 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 48,750 · Balance 0 F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-02 · Disposition to issuer · Disposed 24,375 · Balance 0 F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-07-02 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-07-02 · Disposition to issuer · Disposed 32,500 · Balance 0 F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-07-02 · Disposition to issuer · Disposed 371,545 · Balance 0 F7: In connection with the Merger, these options were accelerated and canceled without payment.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-07-02 · Disposition to issuer · Disposed 32,291 · Balance 0 F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.

F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").

F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.

F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F7: In connection with the Merger, these options were accelerated and canceled without payment.

F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 15, 2019 Filed Jan 15, 2019 20:14 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	868	$24.25	$21,049.00	Disclosure SEC source: 0001209191-19-003822 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,932 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 12, 2019 Filed Jan 15, 2019 20:14 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	2,125	$0.00	$0.00	Disclosure SEC source: 0001209191-19-003822 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 F1 · shares: Each Performance Stock Unit ("PSU") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 2,125 PSUs vested on January 12, 2019 upon certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States. An additional 2,125 PSUs will vest on the first anniversary of the Certification Date. Read SEC document
September 04, 2018 Filed Sep 5, 2018 19:27 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	8,884	$29.18	$259,203.14	Disclosure SEC source: 0001209191-18-049675 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Interim Co-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
August 31, 2018 Filed Sep 5, 2018 19:27 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	17,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-049675 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Interim Co-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% vested on August 31, 2018. Read SEC document
August 23, 2018 Filed Aug 28, 2018 18:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	8,794	$26.05	$229,083.70	Disclosure SEC source: 0001209191-18-048725 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Interim Co-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,477 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
July 28, 2018 Filed Aug 28, 2018 18:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	17,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-048725 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Interim Co-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018. Read SEC document
June 06, 2018 Filed Jun 7, 2018 17:02 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $27.98	$0.00	Disclosure SEC source: 0001209191-18-036414 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 6, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
May 22, 2018 Filed May 24, 2018 20:04 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	2,514	$40.82	$102,621.48	Disclosure SEC source: 0001209191-18-033233 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,271 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
May 22, 2018 Filed May 24, 2018 20:04 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	5,859	$0.00	$0.00	Disclosure SEC source: 0001209191-18-033233 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,785 F1 · shares: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 5,859 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 5,859 PSUs will vest on the first anniversary of the Certification Date. Read SEC document
March 08, 2018 Filed Mar 12, 2018 19:58 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	2,009	$39.16	$78,666.61	Disclosure SEC source: 0001209191-18-018991 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,442 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.06 to $39.28, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4. F5 · balance_after: This number includes 31,040 unvested RSUs. Read SEC document
March 08, 2018 Filed Mar 12, 2018 19:58 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	10,465	$38.69	$404,864.69	Disclosure SEC source: 0001209191-18-018991 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,451 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $39.02, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4. F3 · balance_after: This number includes 31,040 unvested RSUs. Read SEC document
March 02, 2018 Filed Mar 6, 2018 17:48 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	6,735	$32.53	$219,089.55	Disclosure SEC source: 0001209191-18-017408 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,040 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 31, 2018 Filed Feb 2, 2018 19:57 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	42,500	$0.00 Strike: $51.31	$0.00	Disclosure SEC source: 0001209191-18-007241 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2028-01-30 F2 · derivative.exercise_date: The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 31, 2018 Filed Feb 2, 2018 19:57 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	10,625	$0.00	$0.00	Disclosure SEC source: 0001209191-18-007241 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
October 10, 2017 Filed Oct 11, 2017 19:27 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $21.69	$0.00	Disclosure SEC source: 0001209191-17-056693 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest and become exercisable on each of 10/10/2018, 10/10/2019 and 10/10/2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document
August 16, 2017 Filed Aug 18, 2017 16:48 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	3,635	$54.86	$199,416.10	Disclosure SEC source: 0001209191-17-049636 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
July 11, 2017 Filed Jul 13, 2017 17:54 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	23,350	$0.00 Strike: $25.08	$0.00	Disclosure SEC source: 0001209191-17-045083 · doc4.xml · derivative · entry 3 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,390 Underlying: Common Stock · 23,350 shares Expires 2024-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
July 11, 2017 Filed Jul 13, 2017 17:54 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	23,350	$60.00	$1,401,000.00	Disclosure SEC source: 0001209191-17-045083 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
July 11, 2017 Filed Jul 13, 2017 17:54 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	23,350	$25.08	$585,618.00	Disclosure SEC source: 0001209191-17-045083 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	6,885	$0.00 Strike: $25.08	$0.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · derivative · entry 13 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,177 Underlying: Common Stock · 6,885 shares Expires 2024-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	60,937	$0.00 Strike: $22.06	$0.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · derivative · entry 12 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 60,937 shares Expires 2023-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	16,029	$0.00 Strike: $9.50	$0.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · derivative · entry 11 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,029 shares Expires 2022-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	1,191	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · derivative · entry 10 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,191 shares Expires 2022-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	8,350	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · derivative · entry 9 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,350 shares Expires 2022-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	4,493	$56.61	$254,348.73	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 8 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.43 to $56.92, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	46,478	$55.83	$2,594,866.74	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 7 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,493 F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.41 to $56.40, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	42,421	$54.94	$2,330,609.74	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 6 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,971 F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.41 to $55.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	6,885	$25.08	$172,675.80	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 5 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	60,937	$22.06	$1,344,270.22	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 4 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	16,029	$9.50	$152,275.50	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	1,191	$7.00	$8,337.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
June 27, 2017 Filed Jun 28, 2017 18:05 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	8,350	$7.00	$58,450.00	Disclosure SEC source: 0001209191-17-042169 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document
March 15, 2017 Filed Mar 16, 2017 18:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	4,300	$0.00 Strike: $8.50	$0.00	Disclosure SEC source: 0001209191-17-021197 · doc4.xml · derivative · entry 5 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,300 shares Expires 2021-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2016. Read SEC document
March 15, 2017 Filed Mar 16, 2017 18:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionStock Option (Right to Buy) · Derivative	5,935	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001209191-17-021197 · doc4.xml · derivative · entry 4 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 5,935 shares Expires 2022-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2016. Read SEC document
March 15, 2017 Filed Mar 16, 2017 18:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	10,235	$40.02	$409,604.70	Disclosure SEC source: 0001209191-17-021197 · doc4.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.18, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2016. Read SEC document
March 15, 2017 Filed Mar 16, 2017 18:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	4,300	$8.50	$36,550.00	Disclosure SEC source: 0001209191-17-021197 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2016. Read SEC document
March 15, 2017 Filed Mar 16, 2017 18:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionCommon Stock	5,935	$7.00	$41,545.00	Disclosure SEC source: 0001209191-17-021197 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2016. Read SEC document
March 02, 2017 Filed Mar 3, 2017 17:26 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	5,334	$38.61	$205,945.74	Disclosure SEC source: 0001209191-17-017775 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,767 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 30, 2017 Filed Feb 1, 2017 19:57 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantPerformance Stock Unit · Derivative	15,625	$0.00	$0.00	Disclosure SEC source: 0001209191-17-006888 · doc4.xml · derivative · entry 3 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2027-01-30 F3 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the "Certification Date") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date. If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest. F3 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the "Certification Date") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date. If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest. Read SEC document
January 30, 2017 Filed Feb 1, 2017 19:57 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	62,500	$0.00 Strike: $25.54	$0.00	Disclosure SEC source: 0001209191-17-006888 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2027-01-30 F2 · derivative.exercise_date: The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2017, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 30, 2017 Filed Feb 1, 2017 19:57 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	15,625	$0.00	$0.00	Disclosure SEC source: 0001209191-17-006888 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.